Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Rises By 15.1%

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 2,360,000 shares, a growth of 15.1% from the March 31st total of 2,050,000 shares. Currently, 4.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 584,200 shares, the short-interest ratio is presently 4.0 days.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Oppenheimer upgraded Aldeyra Therapeutics from a "market perform" rating to an "outperform" rating and set a $10.00 target price on the stock in a report on Wednesday, April 3rd. StockNews.com raised Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, January 29th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd.

Insider Activity at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc acquired 8,374 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were acquired at an average price of $3.25 per share, for a total transaction of $27,215.50. Following the completion of the purchase, the insider now directly owns 8,601,960 shares of the company's stock, valued at $27,956,370. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, major shareholder Perceptive Advisors Llc acquired 8,374 shares of the business's stock in a transaction dated Monday, April 1st. The stock was acquired at an average price of $3.25 per share, for a total transaction of $27,215.50. Following the completion of the acquisition, the insider now directly owns 8,601,960 shares in the company, valued at approximately $27,956,370. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Todd C. Brady sold 97,914 shares of Aldeyra Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $3.27, for a total value of $320,178.78. Following the transaction, the chief executive officer now directly owns 1,556,622 shares in the company, valued at $5,090,153.94. The disclosure for this sale can be found here. Insiders purchased 355,933 shares of company stock worth $1,473,245 in the last 90 days. Corporate insiders own 7.30% of the company's stock.

Institutional Trading of Aldeyra Therapeutics

A number of hedge funds have recently made changes to their positions in ALDX. Prime Capital Investment Advisors LLC purchased a new stake in shares of Aldeyra Therapeutics during the fourth quarter worth $35,000. SG Americas Securities LLC acquired a new position in Aldeyra Therapeutics in the 4th quarter worth about $39,000. NorthRock Partners LLC purchased a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth about $42,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics during the 1st quarter valued at about $49,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Aldeyra Therapeutics by 1,064.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 22,167 shares of the biotechnology company's stock valued at $78,000 after buying an additional 20,264 shares in the last quarter. 59.71% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Stock Up 3.1 %

Shares of ALDX traded up $0.12 during mid-day trading on Monday, reaching $4.05. The company's stock had a trading volume of 393,291 shares, compared to its average volume of 577,878. The company has a market cap of $240.61 million, a price-to-earnings ratio of -6.33 and a beta of 1.51. The business has a fifty day moving average of $3.65 and a 200 day moving average of $3.16. Aldeyra Therapeutics has a 1 year low of $1.42 and a 1 year high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.13. On average, analysts predict that Aldeyra Therapeutics will post -0.14 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.